MEI Pharma (MEIP) Initiates Strategic Realignment

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/17/2026

1. VRNS
2. JBHT
3. CRWV
4. TSLA
5. SCHW
6. GPRK
7. TRV
8. TFC
9. USB
10. SPY

Go back to MEI Pharma (MEIP) Initiates Strategic Realignment

MEI Pharma Initiates Strategic Realignment

December 5, 2022 5:01 PM EST

Company continuing development efforts on its two early clinical-stage oncology assets: voruciclib and ME-344

MEI expects existing cash sufficient to fund through clinical data milestones for voruciclib and ME-344

SAN DIEGO--(BUSINESS WIRE)-- MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that it plans to initiate a realignment of its clinical development efforts following the discontinuation of global development outside Japan of its PI3K delta inhibitor, zandelisib. As part of the realignment, the company plans to... More